Myriad Oncology

Get streamlined answers to take action fast, with comprehensive germline testing, tumor profiling, and companion diagnostic HRD testing.

Learn more

Genetic insights that optimize patient outcomes

Myriad’s clinically actionable, comprehensive germline and somatic genetic tests help you determine  the most effective treatments based on unique cancer features—improving each patient’s chance for a healthy future.

I’m a provider

I’m a patient

Comprehensive accuracy at the speed of care

Advancing surgical outcomes for germline testing

Your patients need your treatment guidance, fast. MyRisk® Hereditary cancer Test draws on Myriad’s 30+ years of genetic expertise to analyze 48 clinically actionable genes across 11 cancer types, and gives you the industry’s most accurate and actionable germline result.

Elevate patient care for those with cancer, and those needing preventive intervention.

  • Industry-leading variant classification for the accuracy you need.
  • Expedited results within 2 weeks, with a 1-week priority for breast cancer, ensuring no delay in critical care.
  • Treatment-focused reporting includes actionable summaries with clear insights to help surgical outcomes. 
  • Access to affordable testing and resources to help your patients navigate options.
  • Fast, simple workflow solutions provide pre- and post-test education and administrative support.

Find out more about MyRisk Hereditary Cancer Test.

Learn more

Speed the path to treatment

Comprehensive germline and somatic biomarker testing from a single, trusted source

Your patients need every step toward cancer treatment to happen quickly. Get streamlined answers to take action fast, with comprehensive germline testing, tumor profiling, and companion diagnostic HRD testing.

Save precious time by identifying comprehensive treatment options, fast.

  • Comprehensive patient summary sheet highlights actionable results across all tests for faster review.
  • Lifetime VUS updates inform patient care along their entire cancer treatment journey.
  • Concordance checks between germline and somatic testing give you a consistent answer every time.
  • Access to affordable testing and resources to help your patients navigate options.
  • Fast, simple workflow solutions provide pre- and post-test education and administrative support.

Find out more about Myriad’s comprehensive germline and somatic testing.

Learn more

The Myriad Oncology portfolio offers testing solutions for every step in your patients’ and their families’ journeys

  • Germline Tests

    Germline hereditary cancer test capable of identifying risk and providing insights for treatment options for 11 hereditary cancers.

    For providers
  • Tumor Profiling

    Precise™ Tumor is a pan-cancer, comprehensive laboratory test that uses state-of-the-art, next-generation sequencing to discover and target important variants within tumors.

    For providers
  • HRD Status

    The most comprehensive FDA-approved tumor test that determines HRD status in women with ovarian cancer.

    For providers

  • FDA-approved germline companion diagnostic test for patients with breast, ovarian, pancreatic and prostate cancer.

    For providers
  • IHC Stains

    FDA-approved assay to identify patients with ovarian cancer who may qualify for treatment with mirvetuximab*

    For providers

  • Offered together with Precise Tumor™ to measure protein expression and identify patients who may benefit from immunotherapy

  • for newly diagnosed and untreated patients

    Prolaris® is a molecular diagnostic test that helps determine the aggressiveness of a prostate cancer tumor to guide the best treatment decisions for prostate cancer patients.

    For patients For providers
Previous Test
    Next Test

    Inform critical choices with definitive variant classification

    Industry’s lowest rate of BRCA1/2 variants of uncertain significance1,2 for the accuracy you need.

    • Myriad tests have provided definitive classification for up to 63% of variants other labs could not.1
    • Additional RNA analysis is available to all patients who receive an eligible VUS result with MyRisk.
    • Myriad will notify the patient’s care team when RNA analysis could help classify variants-regardless of when, where, or how the MyRisk test was submitted.

    Find out more about our lifetime commitment to variant classification.

    Learn more

    Inform critical choices with definitive variant classification

    Industry’s lowest rate of BRCA1/2 variants of uncertain significance 1,2 for the accuracy you need.

    • Myriad tests have provided definitive classification for up to 63% of variants other labs could not.1
    • Additional RNA analysis is available to all patients who receive an eligible VUS result with MyRisk.
    • Myriad will notify the patient’s care team when RNA analysis could help classify variants-regardless of when, where, or how the MyRisk test was submitted.

    Find out more about our lifetime commitment to variant classification.

    Learn more

    Affordable genetic testing

    Excellent insurance coverage

    Many patients pay $0 for genetic testing.

    Clear cost estimates

    Patients will know what their costs are—if any—before the test is run.

    Financial assistance

    Myriad offers assistance to manage out-of-pocket costs.

    Learn more

    Myriad provides a customizable suite of services and workflow solutions to streamline testing without added cost.

    1. Patient Identification

    OPTIONS

    • Digital Screening with MyGeneHistory
    • Radiology Information Systems
    • Mammography Information Systems

    2. Pre-Test Education
    (with Board-Certified Genetic Counselor)

    INCLUDES

    • Individualized Education (on-demand)
    • Follow-up Documentation (Pre-populated test request form, three-generation pedigree, chart notes)

    3. Ordering

    OPTIONS

    • Online Portal
    • Virtual/Paper Orders
    • EMR Integrations
    • Phlebotomy Support
    • Technical/Ordering Support

    4. Affordability

    INCLUDES

    • Personalized Cost Estimates
    • 9/10 Patients Pay $0 ($54 average)
    • Financial Assistance and Payment Plans Available

    5. Results

    INCLUDES

    • Personalized Tyrer-Cuzick/RiskScore with a 5-year and lifetime risk (when applicable)
    • Online Portal or Results by Mail
    • EMR Integration
    • Medical Management Tool Included

    6. Post-test Discussions
    (with Board-Certified Counselor)

    INCLUDES

    • Individualized Discussion of Results (on- demand or scheduled)
    • Detailed Summary of Notes

    Myriad provides a customizable suite of services and workflow solutions to streamline testing without added cost.

    1. Patient Identification

    OPTIONS

    • Digital Screening with MyGeneHistory
    • Radiology Information Systems
    • Mammography Information Systems

    2. Pre-Test Education
    (with Board-Certified Genetic Counselor)

    INCLUDES

    • Individualized Education (on-demand)
    • Follow-up Documentation (Pre-populated test request form, three-generation pedigree, chart notes)

    3. Ordering

    OPTIONS

    • Online Portal
    • Virtual/Paper Orders
    • EMR Integrations
    • Phlebotomy Support
    • Technical/Ordering Support

    4. Affordability

    INCLUDES

    • Personalized Cost Estimates
    • 9/10 Patients Pay $0 ($54 average)
    • Financial Assistance and Payment Plans Available

    5. Results

    INCLUDES

    • Personalized Tyrer-Cuzick/RiskScore with a 5-year and lifetime risk (when applicable)
    • Online Portal or Results by Mail
    • EMR Integration
    • Medical Management Tool Included

    6. Post-test Discussions
    (with Board-Certified Counselor)

    INCLUDES

    • Individualized Discussion of Results (on- demand or scheduled)
    • Detailed Summary of Notes

    Latest research and publications

    Groundbreaking research to support patient health

    Myriad conducts industry-leading, innovative genetic research and testing to further the science of care. Our scientific studies have been published in prominent journals and at global conferences and feature breakthrough insights for improved patient treatments and outcomes.

    See our publications

    Get started with Myriad Oncology

    Request more information from our team.

    References:
    1. Gradishar W, et al. Clinical variant classification: a comparison of public databases and a commercial testing laboratory. The Oncologist. 2017; 22(7):797–803. doi: 10.1634/theoncologist.2016-0431
    2. Mundt E, et al. Driving Down the Rate of Variants of Uncertain Significance as the Myriad MyRisk® Multigene Panel Grows [White paper]. Myriad Genetics. Oct 2019.

    Locations

    United States
    Europe
    Japan